Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Oh, how the drama continues...
Seriously? So now we're going after people who may have gone to church with him? ROFLMAO!!!!
NOBODY cares about a check-bouncing charge from a college kid FORTY years ago!!! LMAO!!!!
I'll say this for 101st time - WRONG, WRONG, WRONG! Okay make that 103rd time. Who cares about a 40 year-old bounced check? LMAO!!!
...and now 19 months later, we're talking "human sacrifices". The only thing "expanding" around here is the drama!
Too MUCH drama! Laughing harder now...thanks
Wrong! Laws have changed in the last 40 years.
Sure, 19 months later. Any day now...
He bounced a check in college for $100, and email is not "unjust enrichment". But please show where he was convicted of securities fraud? Better yet, please show where he was charged with it.
Waiting...(and laughing)
His "yes men"?? And who are his "yes men" that are getting felony charges? LMAO!!!
Ah...the saga continues. Can't wait for the movie to come out so that I can break out the popcorn and Good & Plentys!
Perhaps therapy will help.
Can I buy I vowel?
I'd like to see the TRUTH! I know a LOT of people who would like to see the TRUTH!
WRONG! Complete BS!!! Show me where the FDA said to "halt the trials because it doesn't work". Laughing...
It's their "opinion" because after 18 months, they still can't provide a single fact showing the target of the investigation. It's all speculation and word salad, nothing more.
You're 100% correct! Any time the former failed CEO Tony is mentioned, the former failed 13D'ers go berserk! I hear some of them lost their ass by buying over $200k in convertible notes from Brucey, who now owns them instead of the LL they were trying to steal from CYDY last year.
Wrong! How do they issue subpoenas without disclosing an investigation? And why would it take over 18 months if they had ANY evidence?? LMAO!!!
Obviously NOT. If there was ANY illegal activity that required a grand jury, it would have been announced a LONG TIME AGO. The mere fact that it's been over a year and a half is CLEAR evidence they found NO evidence of ANY wrong doing by CYDY or their former employees. Any claim otherwise is nothing more then false hope!
She NEVER said "WE are investigation". There's a HUGE difference between that and saying CYDY received subpoenas about an SEC/DOJ investigation. NOBODY knows what was being investigated. It's common knowledge the DOJ does NOT discuss ongoing or closed investigations which is why NOBODY has provided a sliver of proof of what is being investigated, only conjectures and false theories. Subpoenas are usually given to witnesses and not the targets of the investigation. Anyone who claims they know the target of the investigation is basing it purely on biased speculation without proof. Given the investigation was initiated over a year and a half ago, and there's been no actions from the SEC/DOJ since then, leads me to believe it was a nothing burger which is unfortunate for the shorts who continue to push the failed narrative that the former CEO is going to jail. The shorts are the only ones who care about someone who hasn't been the CEO since early January!
BS! She never said that!
CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to its Scientific Board of Advisors; Dr. Jay Lalezari to Serve as Outside Scientific Advisor
VANCOUVER, Washington, May 13, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the addition of Dr. Paul Edison, Dr. Kabir Mody, and Dr. Otto Yang to the Company’s Scientific Board of Advisors. In addition, Dr. Jay Lalezari has agreed to serve as an outside Scientific Advisor to the Company.
Dr. Paul Edison is a Senior Clinical Lecturer in Neuroscience in the Department of Brain Sciences at Imperial College London and an honorary Professor at Cardiff University. He is also the Editor-in-Chief of the journal Brain Connectivity. After his clinical training (MD), Dr. Edison received his MPhil and Ph.D. from Imperial College London, and then completed his higher training in London Deanery and obtained his CCT from the Postgraduate Medical Education and Training Board. He then became a Fellow of the Royal College of Physicians, Ireland, and Fellow of the Royal College of Physicians, UK. He has published in such highly regarded journals as Brain, Annals of Neurology, and Neurology, and has received grants from the Medical Research Council, NIHR/HEFCE, Alzheimer’s Society, Alzheimer’s Research UK, Alzheimer’s Drug Discovery Foundation US, and other funders. He collaborates closely with Novo Nordisk, GE Healthcare, Novartis, Piramal Life Sciences, and Astra Zeneca. He has also received several best paper awards internationally and published in leading scientific journals. His work now focuses on neuroinflammation and the interplay between inflammation and immunity in neurodegenerative and neuroinflammatory disease, and relating these with genetic information. He is also evaluating the methods of modulating inflammation and amyloid in Alzheimer’s disease, and the influence of cardiometabolic factors on the development of neurodegenerative diseases by means of clinical and pre-clinical studies.
Dr. Kabir Mody is the Medical Director at IMV, Inc. and a board-certified medical oncologist. He brings a wealth of experience and knowledge in oncology and immuno-oncology accumulated while working at Mayo Clinic as an academic oncologist focused on GI oncology, particularly cancers of the liver and the pancreas. Dr. Mody received his MD from St. George's University School of Medicine, and completed his residency at St. Luke’s-Roosevelt Hospital in New York City, and a fellowship at Dartmouth Hitchcock Medical Center in New Hampshire. He has co-authored numerous papers and book chapters, including many on the biology and novel treatment strategies of liver and pancreas malignancies, and has been actively involved in leading both clinical and lab-based research on cancers of the liver and pancreas.
Dr. Otto Yang is a Professor of Medicine, Infectious Diseases, Microbiology, Immunology & Molecular Genetics at UCLA and has a background in clinical infectious diseases. His laboratory specializes in T cell immunology in HIV infection, relevant to developing immune therapies and vaccines for HIV and potentially other diseases, including cancer and other viral infections. He received his MD degree from Brown University, with subsequent residency training at NYU-Bellevue Hospital and subspecialty/postdoctoral training at Harvard-Massachusetts General Hospital. He then pursued a fellowship at Massachusetts General Hospital, where he developed a research program studying the role of CD8+ T lymphocytes (CTL, which are killer T cells that can destroy cells infected with viruses or which are malignant) in HIV-1 pathogenesis. A more recent research interest has been the role of CTL in the development of rejection in organ transplant patients. Dr. Yang has begun working with the new composite tissue transplantation program at UCLA, which will perform hand and face transplants, studying the role of this arm of immunity in causing tissue rejection. Dr. Yang is a frequent lecturer, has received numerous research grants and funding for his work and published over 180 peer-reviewed articles, and holds numerous patents in HIV and Immunology.
Dr. Jacob (Jay) Lalezari has agreed to serve as an outside Scientific Advisor to CytoDyn without compensation. Dr. Lalezari has been the CEO and Medical Director of Quest Clinical Research since 1997. He received his MD degree from the University of Pennsylvania and his MA from the University of Virginia. He also received a BA from the University of Rochester. He received his board certification from the American Board of Internal Medicine. He briefly served as interim Chief Medical Officer of CytoDyn during 2020, as well as Chief Medical Officer of Virion Therapeutics. Dr. Lalezari has served as Principal Investigator for Phase I, II, and III clinical studies of new therapies for such viral diseases as HIV/AIDS, CMV, HPV, HSV, Hepatitis B and C, Influenza, RSV, and COVID-19, including clinical trials conducted by the Company. He has published extensively and is a well-regarded international speaker and patient advocate.
https://www.cytodyn.com/newsroom/press-releases/detail/600/cytodyn-announces-the-addition-of-leading-experts-in
Please show where selling more shares than were bought is proof it was the PIPE holders that were selling and not retail. Laughing!
Want a real laugh? I see the real scam NWBO is still down over 50% this week when compared to CYDY. I'll stick with CYDY!
Laughing...
Nope! I don't own any NWBO stock. LMAO
Yep. Closed yesterday at $1.82 and dropped to .38 this morning, within 2 cents of CYDY in just a couple of hours. And "that is how it's done!" You predicted .20 last week, and it came close, but not with CYDY!
ROFLMAO
Unfortunately, due to the paid pumpers & dumpsters, what they have is a 70% loss! But I'm sure how we'll hear how some sold minutes before the drop! LMAO
No thank you! I've seen too much! I don't recall seeing CYDY plunge 70% in one day. That turd is just circling the bowl and getting ready to disappear!
Bahahaha
Ouch!!! Down 70%!!! ROFLMAO!!!
This turd is swirling around the bowl! Who in the hell would buy it?? Now that's a "bonafide" question!
The company's name is CytoDyn.
My "reasoning" hasn't produced ANY losses. LOL
Where is the proof that management isn't paying any vendors anything with the proceeds from the latest fund raising?
And yet still nothing to support this claim. I agree this is ridiculous. LMAO
Then why wasn't it posted here?
And THAT is ALL that is known, yet others continue to push the false narrative that "SK flipped on NP for illegal activity" even though NOBODY knows the target or reason for the investigation. Pure fantasy at this point!
DEBUNKING the DEBUNKED:
"DOJ generally will not confirm the existence of or otherwise comment about ongoing investigations."
https://www.justice.gov/jm/jm-1-7000-media-relations#:~:text=Where%20the%20investigation%20is%20being%20handled%20by%20the,existence%20of%20or%20otherwise%20comment%20about%20ongoing%20investigations.
And this has somehow been misconstrued to mean "Kelly flipped on NP for his illegal activities". ROFLMAO!!!!! Still not ONE iota of evidence of this from the SEC/DOJ. And why not? Because it's common knowledge the DOJ doesn't discuss the targets of ongoing investigations, and that's assuming it's still ongoing given it was mentioned over a year ago.
Please show me where I said or implied that, or better yet, show me where the SEC/DOJ explained the target of their investigation that was announced over a year ago. Laughing...
Wrong! You said we can't say NASH met its endpoints even though it clearly says it met its endpoints. Laughing...
Wrong again!
Promising Phase II Results for Hard-to-Treat Liver Disease
CytoDyn shared positive results from its Phase II clinical study on the effectiveness of leronlimab against nonalcoholic steatohepatitis (NASH).
The NASH trial achieved the primary endpoint of proton density fat fraction (PDFF) and the secondary endpoint of cT1. PDFF is an MRI-derived biomarker for fatty deposition, while cT1 is an iron-corrected T1 mapping indicator of fibrosis and liver inflammation. Both endpoints were used to assess the NASH risk.
https://www.biospace.com/article/cytodyn-posts-positive-results-from-phase-ii-nash-trial-for-leronlimab/
The drug met its primary/secondary endpoints for the P3 HIV trial, and met the P2 NASH primary endpoints, and has shown incredible efficacy with mTNBC. Laughing...